A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer
about
Clearance of pathological antibodies using biomimetic nanoparticles.Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma.Liposomally targeted cytotoxic drugs for the treatment of cancer.Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacyCancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.Toxicity of the topoisomerase II inhibitors.HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy.Anthracycline cardiotoxicity.Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.The treatment of breast cancer using liposome technology.Targeting mitochondrial function for the treatment of breast cancer.Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art.A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma.What Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near Future
P2860
Q34218004-5816F7EB-80F2-468A-836A-269F806F0A7AQ34563378-A219C4EE-01DC-48A8-9CC7-B5E66629A00FQ34795330-0364E35E-8F4F-4248-B0E5-4ABC70B37A9BQ35051019-C45904E3-E6DB-4485-86CD-869932DBD57AQ35679856-93F70297-44E1-4654-BAE6-0415A9B0E847Q35786517-82D7C2E4-C8AD-42EC-8F91-AD85FE04B5BBQ36081997-D4E46DF3-391E-4263-874E-275957B57205Q36448817-B86ECB1E-7A80-4396-B1C8-129D7C20473AQ36624983-130A9CDC-C2A8-44E1-AE6C-81B88B13D414Q37059896-7D6FC23C-CD28-474A-A254-D006EC375CD5Q38002854-603D8880-C4A1-45DC-8FDB-494CA405A2F2Q38264534-9A3420E1-27BE-4E69-9514-96933F07515DQ38693952-87BB3981-4207-4381-AB72-FB5628F7D813Q46606526-6630C7E5-0F96-451E-A65B-16968BC160F8Q59128232-8D08D4C2-5D29-4AE1-81E4-9AF3B1788C13
P2860
A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
A phase I dose-escalating stud ...... n, in metastatic breast cancer
@ast
A phase I dose-escalating stud ...... n, in metastatic breast cancer
@en
type
label
A phase I dose-escalating stud ...... n, in metastatic breast cancer
@ast
A phase I dose-escalating stud ...... n, in metastatic breast cancer
@en
prefLabel
A phase I dose-escalating stud ...... n, in metastatic breast cancer
@ast
A phase I dose-escalating stud ...... n, in metastatic breast cancer
@en
P2093
P2860
P356
P1476
A phase I dose-escalating stud ...... n, in metastatic breast cancer
@en
P2093
A L Thomas
K J O'Byrne
M DeCatris
R A Sharma
W P Steward
P2860
P2888
P356
10.1038/SJ.BJC.6600344
P407
P577
2002-07-01T00:00:00Z